Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787722 | 0.75 | RAB9A (0.50) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL16815729 | 0.74 | RAB9A (0.54) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL8539040 | 0.73 | P2RX7 (0.38) | RAB9ANPC1SMN1; SMN2LMNAGAA | |
| SCHEMBL5203291 | 0.72 | CHEK1 (0.48) | LMNAGAAHTTMAPT | |
| SCHEMBL28789382 | 0.71 | RAB9A (0.56) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL2846514 | 0.70 | HIF1A (0.51) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL1509570 | 0.70 | RAB9A (0.54) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL9582152 | 0.70 | RAB9A (0.54) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL12092479 | 0.70 | RAB9A (0.54) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL9171005 | 0.70 | RAB9A (0.54) | RAB9ANPC1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358181-B1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| EP-1358181-A1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030199532-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | KERTESZ DENIS JOHN (US) | 2003-10-23 | — | — | US | disclosed |
| US-6552028-B2 | Inhibiting the binding of eotaxin to chemokine-3 (ccr-3) receptor; antiasthmatics | SYNTEX (U.S.A.) LLC | 2003-04-22 | — | — | US | disclosed |
| US-20020198255-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002050064-A1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199532-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCR4 | RAB9A 2822/4885NPC1 961/4885NFKB1 1954/4885 |
| US-20020198255-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCR4 | RAB9A 2822/4885NPC1 961/4885NFKB1 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.